Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edesa Biotech Inc (EDSA)
NASDAQ:EDSA
Edesa Biotech (EDSA) Stock Price & Analysis
241 Followers
EDSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.46 - $8.61
Previous Close$4.47
Volume2.36K
Average Volume (3M)12.69K
Market Cap
$14.16M
Enterprise Value$9.97M
Total Cash (Recent Filing)$4.27M
Total Debt (Recent Filing)$78.31K
Price to Earnings (P/E)-5.4
Beta1.58
Next Earnings
May 10, 2024EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding3,171,760
10 Day Avg. Volume3,551
30 Day Avg. Volume12,685
Standard Deviation0.31
R-Squared0.00292
Alpha-0.00359
Financial Highlights & Ratios
Price to Book (P/B)3.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$21.00Price Target Upside369.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Edesa Biotech News
PremiumCompany Announcements
Edesa Biotech Showcases Innovation at Investor Conference
PremiumCompany Announcements
Edesa Biotech Engages Investors at Global Conferences
PremiumCompany Announcements
Edesa Biotech Shines at Autoimmune Conference
PremiumCompany Announcements
Edesa Biotech Showcases Innovations at Healthcare Conference
PremiumCompany Announcements
Edesa Biotech Showcases Innovations at Dermatology Events
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive final results from a Phase 2b dose-ranging study with EB01 in patients with moderate-to-severe allergic contact dermatitis.
Government FundingFunding of up to C$23M from the Canadian government toward development of EB05 has been secured.
Regulatory ApprovalHealth Canada approved the company’s proposed harmonization in the design of its Phase 3 with EB05 as a treatment for acute respiratory distress syndrome (ARDS).
Bears Say
Investment RisksRisks to the investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, and potential to raise additional funds.
Product DevelopmentAdjusting EB02 development timeline and removing forecast for EB02’s contribution to models due to revised regulatory approval timelines.
Stock ValuationAdjusted PT to $21 versus prior $70, reflecting the effect of the reverse stock split.
---
EDSA FAQ
What was Edesa Biotech Inc’s price range in the past 12 months?
Edesa Biotech Inc lowest stock price was $2.46 and its highest was $8.61 in the past 12 months.
What is Edesa Biotech Inc’s market cap?
Currently, no data Available
When is Edesa Biotech Inc’s upcoming earnings report date?
Edesa Biotech Inc’s upcoming earnings report date is May 10, 2024 which is in 14 days.
How were Edesa Biotech Inc’s earnings last quarter?
Edesa Biotech Inc released its earnings results on Feb 09, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$1.21 by $0.67.
Is Edesa Biotech Inc overvalued?
According to Wall Street analysts Edesa Biotech Inc’s price is currently Undervalued.
Does Edesa Biotech Inc pay dividends?
Edesa Biotech Inc does not currently pay dividends.
What is Edesa Biotech Inc’s EPS estimate?
Edesa Biotech Inc’s EPS estimate is -$0.69.
How many shares outstanding does Edesa Biotech Inc have?
Edesa Biotech Inc has 3,171,760 shares outstanding.
What happened to Edesa Biotech Inc’s price movement after its last earnings report?
Edesa Biotech Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$1.21. Following the earnings report the stock price went up 7.867%.
Which hedge fund is a major shareholder of Edesa Biotech Inc?
Currently, no hedge funds are holding shares in EDSA
---
Edesa Biotech Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (369.97% Upside)
$21.00 (369.97% Upside)
Insider Transactions
Bought Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.91%
12-Months-Change
Fundamentals
Return on Equity
-95.77%
Trailing 12-Months
Asset Growth
-32.92%
Trailing 12-Months
Company Description
Edesa Biotech Inc
Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.
---
EDSA Stock 12 Months Forecast
Average Price Target
$21.00
▲(369.97% Upside)
Technical Analysis
Best Analysts Covering EDSA
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-42.49%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -42.49% per trade.
---